Observing others argue on your part in an area you are not in can cause a certain type of political discomfort. That is the position British car makers found themselves in this week, as the European car industry's own lobby group pleaded with Brussels not to lock UK-built vehicles out of a market that, for companies like BMW's Mini and Nissan's Sunderland plant, is not really foreign at all. It took a German-dominated trade association, not the British government, to make the case that Britain's factories are still functionally European even if its politics no longer are.

The Industrial Accelerator Act was never written with the UK in mind. It exists to keep subsidised Chinese vehicles and components from hollowing out European manufacturing, and it does so by drawing a line around EU membership rather than around industrial reality. Britain, sitting outside that line despite feeding parts, batteries and finished cars into the same supply chains, has to hope that lobbying pressure from firms that happen to own its factories will be enough to win an exemption. It might work this time. But the fact that it has to work at all says something uncomfortable about where the UK now sits in relation to regulatory decisions that shape its economy.

That position is not confined to cars. It is the same position British medicines and medical technology occupy, quietly, in relation to European regulatory architecture, and it deserves more attention from health policymakers than it currently gets. Since Brexit, UK regulatory recognition of EU processes has eroded steadily, batch release and testing requirements have diverged, and the MHRA has been left to build parallel infrastructure for decisions that used to happen once, centrally, in Europe. None of that has caused a crisis yet, because much of the medicines supply chain has continued to function through goodwill, transition arrangements and the sheer scale of pharmaceutical trade between Britain and the continent. Goodwill is not a strategy.

The China dimension makes this sharper still. The same trade imbalance driving Brussels to build walls around its car industry runs through pharmaceutical supply chains too. A significant share of active ingredients and generic components used in NHS medicines originate in Chinese manufacturing, and the EU's growing appetite for industrial protectionism against Beijing will not stop at cars. If Brussels moves to secure its pharmaceutical supply chains the way it is now moving to secure automotive ones, Britain will again be negotiating from outside, hoping that European industry finds it more useful to include the UK than to exclude it.

What the car rules episode demonstrates is not that Britain lacks allies. Acea's intervention shows the opposite, that European industry has real incentives to keep British manufacturing inside the tent. What it demonstrates instead is that the UK government has no consistent mechanism for anticipating these moments before they arrive. Each time, the pattern is the same: a rule is drafted in Brussels without UK input, British industry discovers the exposure late, and diplomatic energy is spent retrospectively trying to claw back an exemption that could have been negotiated in advance had anyone been watching the legislative pipeline early enough.

For NHS leaders and life sciences firms, the lesson is not that a medicines version of this crisis is imminent. It is that the UK's exposure to EU industrial policy, on drugs, devices and diagnostics as much as on cars, is structural and will keep resurfacing in forms nobody quite predicts until the draft text appears. Sir Jim Mackey's DHSC and the life sciences sector more broadly would do well to ask which forthcoming EU frameworks, IAA-adjacent or otherwise, might one day require the same last-minute lobbying that Acea is now doing for Mini and Vauxhall. Waiting for a pharmaceutical equivalent of this week's car story to break would mean discovering the exposure only once it had already become a shortage.